PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease

Nielsen, Mette J.; Dolman, Grace E.; Harris, Rebecca; Frederiksen, Peder; Chalmers, Jane; Grove, Jane I.; Irving, William L.; Karsdal, Morten A.; Patel, Keyur; Leeming, Diana Julie; Guha, Indra Neil

doi:10.1016/j.jhepr.2023.100743

All Outputs (2)

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study (2023)
Journal Article

Objectives To quantify mortality rates for patients successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals and compare these rates with those of the general population. Design Population based cohort study.... Read More about Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.